Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 2, 2017 (9 years ago)

Rugby Aller-chlor

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Microbial contamination of Non-sterile Products; presence of yeast and potential B. cepacia contamination

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Rugby Aller-chlor (Chlorpheniramine Maleate Syrup, USP), 2 mg, 4 fl. oz. (120 mL) plastic bottles, Distributed by: Rugby Laboratories 17177 N. Laurel Park Drive, Suite 233, Livonia, MI 48152 USA --- NDC: 0536-1025-47

Affected NDC 0536-1025-47

Compare with the code on your package — it is the most precise check available.

Drug: Chlorpheniramine

Recalling firm
The Harvard Drug Group
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1122-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Chlorpheniramine recalls

See all
Class II · Moderate risk

Broncochem Cold & Tea

Stability testing failures for one or two of the four active pharmaceutical ingredients among the finished drug products, i.e., Phenylephrine HCL, and/or Chlorpheniramine Maleate.

Ongoing Stability / shelf life Global Corporation NDC 65131-097-12 D-0387-2024

Other recalls by The Harvard Drug Group

All 2017 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026